paxilline has been researched along with Gallbladder Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, YZ; Ge, CY; Lu, XS; Sun, W; Zhang, WZ | 1 |
| Chen, M; Chen, S; Jiang, S; Li, D; Li, J; Liang, L; Liu, Z; Yang, Z; Yuan, Y; Zou, Q | 1 |
| Fan, YZ; Ge, CY; Liu, ZY; Sun, W; Wang, H; Zhang, JT; Zhang, WZ | 1 |
3 other study(ies) available for paxilline and Gallbladder Neoplasms
| Article | Year |
|---|---|
Contribution of the PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas.
Topics: Animals; Female; Focal Adhesion Kinase 1; Gallbladder Neoplasms; Humans; Laminin; Male; Metalloendopeptidases; Mice; Mice, Nude; Neovascularization, Pathologic; Paxillin; Phosphatidylinositol 3-Kinases; Receptor, EphA2; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Paxillin and carbonic anhydrase IX are prognostic markers in gallbladder squamous cell/adenosquamous carcinomas and adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Female; Gallbladder Neoplasms; Humans; Male; Middle Aged; Paxillin; Prognosis | 2014 |
Inhibition of tumor vasculogenic mimicry and prolongation of host survival in highly aggressive gallbladder cancers by norcantharidin via blocking the ephrin type a receptor 2/focal adhesion kinase/paxillin signaling pathway.
Topics: Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Ephrin-A2; Female; Focal Adhesion Protein-Tyrosine Kinases; Gallbladder Neoplasms; Humans; Male; Mice; Microcirculation; Paxillin; Signal Transduction; Survival Analysis; Xenograft Model Antitumor Assays | 2014 |